Provider Profile

Thumbnail
Saint Luke’s Care Member

Provider Profile

Kenneth C Huber, MD

Cardiology, Interventional Cardiology
Call to make an appointment 816-931-1883

Education

Medical School
St. Louis University, St. Louis, MO
Residency
Internal Medicine, Mayo Graduate School of Medicine, Rochester, MN
Fellowship
Cardiovascular Disease, Mayo Graduate School of Medicine, Rochester, MN
Fellowship
Interventional Cardiology, Mayo Graduate School of Medicine, Rochester, MN

Board Certifications

  • American Board of Internal Medicine
  • American Board of Internal Medicine - Subspecialty in Cardiovascular Disease

Academic Titles

  • Clinical Professor of Medicine, University of Missouri–Kansas City School of Medicine

Clinical Interests

  • interventional cardiology
  • percutaneous PFO and ASD closure
  • percutaneous left atrial appendage
  • percutaneous mitral valvuloplasty
  • clinical cardiology

Biography

Dr. Kenneth C. Huber received his medical degree in 1985 from St. Louis University School of Medicine in St. Louis, MO.  He completed his Residency in Internal Medicine at the Mayo Graduate School of Medicine in Rochester, MN where he also completed a Cardiology Fellowship. He is a Fellow of the American College of Cardiology and a Professor of Medicine at the University of Missouri-Kansas City.  Dr. Huber is certified by the American Board of Internal Medicine in Internal Medicine, Cardiovascular Disease, and Interventional Cardiology.  He is a lead investigator in the PROTECT-AF Trial and participated on the FDA Advisory Panel for the Watchman device. Dr. Huber serves as President & CEO of Saint Luke’s Cardiovascular Consultants and Co-Executive Medical Director of the Saint Luke’s Mid America Heart Institute. 

Dr. Huber's practice philosophy is to strive to provide cardiovascular care that is of the highest quality and greatest value for his patients. His focus is patient-centric and evidence-based. He enjoys spending time with his patients and their families, making sure they genuinely understand all aspects regarding the diagnosis and treatment for their condition. 

Saint Luke's News

Special screening uncovers potentially fatal problem in a ‘healthy’ young executive
Joel DeBoer could have been a model for a fitness ad. The active father of three teenagers felt great and enjoyed biking, hiking, skiing, and rock climbing with his family.

Accepted Insurances

  • Aetna Better Health/KanCare (KS Medicaid)
  • Aetna Choice POS II Aexcel Local
  • Aetna Choice POS II Local
  • Aetna Elect Choice POS
  • Aetna Federal Employees Health Benefit Plan HMO
  • Aetna First Health Network (excluding limited benefit plans)
  • Aetna HMO
  • Aetna HMO Local
  • Aetna Managed Choice POS
  • Aetna Medicare Plan (Medicare Advantage HMO, PPO)
  • Aetna Missouri Preferred
  • Aetna Open Choice PPO
  • Aetna Select HMO
  • Aetna Select Local HMO
  • Aetna Signature Administrators (ASA) HMO, POS, PPO
  • Aetna UAW Retiree Medical Benefits Trust (Medicare Advantage HMO, PPO)
  • Aetna Workers Comp
  • Aetna/Coventry Advantra Freedom Medicare Advantage PPO
  • Aetna/Coventry Advantra Freedom Plus Medicare Advantage PPO
  • Aetna/Coventry Advantra Total Care Medicare Advantage PPO
  • BCBS of Kansas (call provider)
  • BCBS of Kansas Blue Choice Preferred Care Blue PPO
  • BCBS of Kansas City Blue Select Plus (UCMO and City of KCMO)
  • BCBS of Kansas City Federal PPO
  • BCBS of Kansas City Freedom Network PPO
  • BCBS of Kansas City Freedom Network Select PPO
  • BCBS of Kansas City Preferred Care
  • BCBS of Kansas City Preferred Care Blue
  • BCBS of Kansas City Traditional
  • BCBS of Kansas Federal
  • BCBS of Kansas Traditional
  • BCBS of Michigan Medicare Advantage PPO
  • Blue KC Medicare Advantage HMO
  • Blue KC Medicare Advantage PPO
  • Century Health Solutions (PPO)
  • Cigna HMO
  • Cigna National POS Open Access
  • Cigna OAP
  • Cigna PPO
  • CompResults/CompAlliance (WC) PPO
  • Health Choice of Northwest Missouri (PPO)
  • Home State Health Plan Missouri Medicaid (Missouri practices)
  • Humana Choice PPO - Medicare Advantage
  • Humana ChoiceCare PPO
  • Humana Community HMO - Medicare Advantage
  • Humana Gold Choice Medicare Advantage PFFS
  • Humana Gold Plus HMO - Medicare Advantage
  • Humana Gold Plus HMO SNP - Medicare Advantage
  • Humana Kansas City PPOx
  • Humana National POS-Open Access Plans
  • Humana PPO
  • Humana Preferred PPO
  • Humana SmartExpress PPO
  • Humana SmartNet PPO
  • Humana SmartSuite PPO
  • HumanaOne PPO
  • Integrated Health Plan PPO
  • Kansas Medicaid
  • Medica Connect
  • Medica Select
  • Medicare
  • Missouri Care Health Plan - Missouri Medicaid (MO practices only)
  • MultiPlan/PCHS (PPO)
  • Occupational Health Management PPO (WC)
  • OHARA Managed Care (WC)
  • Private Healthcare Systems PPO
  • ProviDRs Care Network PPO (formerly WPPA)
  • Sunflower State Health Plan Kansas Medicaid (Kansas practices)
  • TRICARE WEST
  • Triwest Veterans Affairs Patient Centered Community Care
  • United Healthcare - All Savers Insurance Company POS
  • United Healthcare - Choice HMO
  • United Healthcare - Choice Plus POS
  • United Healthcare - Community Plan (KS Practices, KanCare, Kansas Medicaid)
  • United Healthcare - Community Plan (MO practices, Missouri Medicaid)
  • United Healthcare - Definity Health Reimbursement Account POS
  • United Healthcare - Definity Health Savings Account POS
  • United Healthcare - Golden Rule HMO (HMO & PPO)
  • United Healthcare - Indemnity
  • United Healthcare - Managed Indemnity
  • United Healthcare - Options PPO
  • United Healthcare - Select HMO
  • United Healthcare - Select Plus POS
  • United Healthcare - United Health One (Short Term Medical)
  • UnitedHealthcare - AARP Medicare Complete Choice PPO
  • UnitedHealthcare - AARP Medicare Complete HMO
  • UnitedHealthcare - AARP Medicare Complete PPO
  • UnitedHealthcare - Dual Complete SNP PPO
  • UnitedHealthcare - Group Medicare Advantage PPO
  • UnitedHealthcare - Medicare Complete PPO
  • UnitedHealthcare - Medicare Gold SNP PPO
  • UnitedHealthcare - Medicare Silver SNP PPO

Publications

ARTICLES PUBLISHED:

1. Huber KC, Gersh BJ, Sugrue DD, Frye RL, Bailey KR, Ritts RE: T Lymphocyte subsets in patients with idiopathic dilated cardiomyopathy. Int J Cardiol 1989; 22:59 66.

2. Pellikka PA, Behrenbeck T, Huber KC, Gibbons RJ: Measurement of myocardium at risk and salvage in myocardial infarction with ST segment depression: Mayo Clin Proc 1990; 65:1222 1226.

3. Christian TF, Behrenbeck T, Pellikka PA, Huber KC, Chesebro JH,Gibbons RJ: Mismatch of left ventricular function and infarct size demonstrated by Technetium 99 isonitrile imaging after reperfusion therapy for acute myocardial infarction: Identification of myocardial infarction and salvage. J Am Coll Cardiol 1990; 16:1632 1638.

4. Christian TF, Clements IP, Behrenbeck T, Huber KC, Chesebro JH, Gibbons RJ: Estimating infarction size after acute reperfusion therapy for myocardial infarction: Ann Int Med 1991, 114:264 270.

5. Behrenbeck T, Pellikka PA, Huber KC, Bresnahan JF, Gersh BJ, Gibbons RJ: Primary angioplasty in myocardial infarction: assessment of improved myocardial perfusion with Technetium 99 isonitrile: J Am Coll Cardiol 1991; 17:133.

6. Murphy JG, Schwartz RS, Huber KC, Holmes DR: Polymeric stents: Modern alchemy or the future? J Inv Cardiol 1991; 3:144 148.

7. Huber KC, Bresnahan JF, Bresnahan DR, Pellikka PA, Behrenbeck T, Gibbons RJ: Measurement of myocardium at risk by Technetium 99 sestamibi.  Correlation with coronary angiography: J Am Coll Cardiol 1992; 19:67 73.

8. Schwartz RS, Huber KC, Murphy JG, Edwards WD, Camrud AR, Vlietstra RE, Holmes DR: Restenosis and the proportional neointimal response to coronary artery injury: results in a porcine model. J Am Coll Cardiol 1992, 19:267 74.

9. Huber KC, Evans MA, Bresnahan JF, Gibbons RJ, Holmes DR: Outcome of noncardiac operation in patients with severe coronary disease treated with successful preoperative angioplasty. Mayo Clin Proc 1992, 67:15 21.

10. Schwartz RS, Edwards WD, Huber KC, Antoniades LA, Bailey KR, Camrud AR, Jorgenson MA, Holmes DR:  Coronary restenosis: New perspectives and prospects for solution: Mayo Clin Proc 1993;  68:54 62

11. Huber KC, Schwartz RS, Edwards WD, Camrud AR, Bailey KR, Jorgenson M, Holmes DR: Effects of angiotensin converting enzyme inhibition on neointimal proliferation in a porcine coronary model; Am. Heart J. 1993; 125:695-701. 

12. Laster SB, Rutherford BD, McConahay DR, Giorgi LV, Johnson WL, Shimshak TM, Huber KC, Hartzler GO: Directional Atherectomy of Left Main Stenoses: Cath & CV Diagnosis March 1994;33:317-322

13. Laster SB, Rutherford BD, Giorgi LV, Shimshak TM, McConahay DR, Johnson Jr WL, Huber KC, Ligon RW, Hartzler GO.  Results of Direct Percutaneous Transluminal Coronary Angioplasty in Octogenarians.  Am J Cardiol 1996;77:10-13.

14. Huber KC, Gersh BJ, Bailey KR, Schaff HV, Hodge DO, Cha RH, Chesebro JH: Variability in anticoagulation control predicts thromboembolism after mechanical cardiac valve replacement: A 23-year population-based study.  Mayo Clinic Proceedings, 1997;72:1102-1110.

15. Suero JA, Marso SP, Jones PG, Laster SB, Huber KC, Giorgi LV, Johnson WL, Rutherford BD. Procedural Outcomes and Long-Term Survival Among Patients Undergoing Percutaneous Coronary Intervention of a Chronic Total Occlusion in Native Coronary Arteries: A 20 Year Experience. J Am Coll Cardiol 2001: 38:409-414.

16. Marso, SP, Giorgi, LV, Johnson, WL, Huber, KC, Laster, SB, Shelton, CJ, McCallister, BD, Coen, MM, Rutherford, BD: Diabetes mellitus is associated with a shift in the temporal risk profile of in-hospital death after percutaneous coronary intervention: An analysis of 25,223 patients over 20 years. American Heart Journal - April 2002;145:270-7.

17. Marso, SP, Manohar, Gowda, O’Keefe, JH, Coen, MM, McCallister, BD, Giorgi, LV, Huber, KC, Laster, SB, Johnson, WL, Rutherford, BD.   Improving In-hospital Mortality in the Setting of an Increasing Risk Profile Among Patients Undergoing Catheter-Based Reperfusion for an Acute Myocardial Infarction Without Cardiogenic Shock: The Journal of Invasive Cardiology December 2003, Vol. 15, No. 12;711-716.

18. Corpus R A., House JA, Marso SP, Grantham JA, Huber, KC, Laster SB, Johnson WL, Daniel WC, Barth CW, Lee, Giorgi V, Rutherford BD: Multivessel  Percutaneous Coronary Intervention in Patients with Multivessel Disease and Acute Myocardial Infarction: American Heart Journal 2004;148:493-500.

19. Main ML, Latus GG, Magalski, A, Huber, KC: Contrast Enhanced Transesophageal Echocardiographic Guidance of Left Atrial Appendage Closure Device Implantation: J Am Soc Echocardiogr 2010; 

 

ABSTRACTS:

1. Huber KC, Gersh BJ, Sugrue DD, Frye RL, Bailey KR, Ritts RE:  T lymphocyte subsets in patients with idiopathic dilated cardiomyopathy and their relationship to duration of symptoms: Circulation 1987; Supp. IV 263:1048.

2. Huber KC, Evans MA, Bresnahan JF, Gibbons RJ, Holmes DR: Outcome of non cardiac surgery in patients with severe coronary disease treated with preoperative angioplasty.  Circulation 1990; Supp III 151:2030.

3. Huber KC, Bresnahan JF, Bresnahan DR, Pellikka PA, Behrenbeck T, Gibbons RJ: Limitations of coronary angioplasty for the determination of myocardium at risk: JACC 1990, Supp A:148A.

4. Huber KC, Schwartz RS, Edwards WD, Camrud AR, Murphy JG, Holmes DR: Effect of angiotensin converting enzyme inhibition on neointimal proliferation in a porcine coronary injury model: Presented at Restenosis Summit May 1991.

5. Schwartz RS, Huber KC, Edwards WD, Camrud AR, Holmes DR: Restenotic coronary ointimal hyperplasia: Developmental stages in a porcine injury model and new insights concerning pathogenesis: Mayo Clinic Proceedings

6. Schwartz RS, Koval TM, Edwards WD, Huber KC, Camrud AR, Jorgenson MA, Browne MD, Vlietstra RE, Holmes DR: External x irradiation: A potential therapy for restenosis? Presented at Restenosis Summit May 1991.

7. Schwartz RS, Forstrom LA, Huber KC, Camrud AR, Jorgenson MA, Murphy JG, Holmes DR: Time course of Indium111 quantitation in a porcine restenosis model: Presented at Restenosis Summit May 1991.

8. Schwartz RS, Koval TM, Edwards WD, Huber KC, Camrud AR, Browne K, Vlietstra RE.  Restenosis and External Beam Radiation: Neointimal Proliferation Effects in a Porcine Model.  Circ 1991 Oct;84(4):II-297.

9. Schwartz RS, Huber KC, Edwards WD, Camrud AR, Jorgenson M, Holmes DR.  Coronary Restenosis and the Importance of Mural Thrombus: Results in a Porcine Coronary Model.  Circ 1991 Oct;84(4):II-71.

10. Huber KC, Schwartz RS, Edwards WD, Camrud AR, Jorgenson MA, Holmes DR: Restenosis and angiotensin converting enzyme  inhibition: Effects on neointimal proliferation in a porcine coronary injury model.  (Presented at AHA November 1991.)

11. Huber KC, Gersh BJ, Bailey KR, Hodge DO, Chesebro JH: Variability in anticoagulation control predicts thromboembolism: A 23 year population based study: (Presented at AHA November 1991.)

12. Huber KC, Schwartz RS, Edwards WD, Camrud AR, Holmes DR: Severe medial cell injury does not prevent neointimal proliferation: Histopathology following microwave angioplasty in a porcine coronary restenosis model: (Presented at ACC 1992).

13. Schwartz RS, Huber KC, Edwards WD, Bowie EJW, Nichols WL, Camrud AR, Jorgenson MA, Holmes DR:  Restenosis and homozygous von Willebrand's disease: Studies in a porcine coronary model: (Presented at ACC 1992.)

14. Schwartz RS, Huber KC, Edwards WD, Taswell HF, Camrud AR, Jorgenson MA, Holmes DR:  Native fibrin film as a biocompatible, absorbable material for intracoronary stent implant and drug delivery.  (Presented at ACC 1992.)

15. Laster SB, Rutherford BD, McConahay DR, Giorgi LV, Johnson WL, Shimshak TM, Huber KC, Ligon RW, Hartzler GO. Mid America Heart Institute: Is multivessel revascularization during direct infarct angioplasty safe? (Society for Cardiac Angiography & Interventions May 1994.)

16. Shimshak, TM, Giorgi LV, McConahay, DR, Johnson, WL, Rutherford, BD, Huber, KC, Ligon, R, Hartzler, GO, Early economics of revascularization – CABG vs PTCA: JA Coll Cardiology February 1994:  402A.

17. Cavero, PG, Ligon, RW, Rutherford, BD, McConahay, DR, Johnson, WL, Giorgi, LV, Shimshak, TM, Huber, KC, Hartzler, GO.  Primary angioplasty for acute myocardial infarction in patients presenting six hours after onset of symptoms: Benefit of late reperfusion: Cath and CV Diagn 1994;32(1):86A.

18. Laster SB, Rutherford BD, McConahay DR, Giorgi LV, Johnson WL, Shimshak TM, Huber KC, Hartzler GO.  Is Direct Infarct Angioplasty the Preferred Reperfusion Therapy in Octogenarians?  Circ 1994;90(4):I-169.

19. Rutherford, BD, Jones, PG, Vacek, JL, Johnson, WL, Jr., Giorgi, LV, Huber KC, Laster, SB: Multiple vessel stenting compared to multiple vessel angioplasty:  in-hospital outcome and long-term follow-up. JACC 1999; 33(2):13A.

20. Wischmeyer JB, Huber KC, Johnson WL, Giorgi LV, Laster SB, Daniel WC, Rutherford BD.  Procedural Outcomes of Aorto-Ostial vs Coronary-Ostial Lesions.  J Am Coll Cardiol 1999 Feb;33(2):82A.

21. Daniel, WC, Laster, SB, Jones, PG, Vacek, JL, Johnson, WL, Jr., Giorgi, LV, Huber KC, Rutherford, BD:  Risk factors predicting in-hospital mortality following balloon angioplasty versus elective stenting.  JACC 1999; 33(2):24A. 

22. Marso, SP, Huber, KC, Giorgi, LV, Johnson, WL, Jr., Laster, SB, Rutherford, BD: Acute and Long-Term Outcomes for a New Generation Stent: Experience in 441 patients with the Medtronic AVE GFX Stent.  JACC 2000 ;1176 (88): 78A.

23. Suero JA, Marso SP, Jones PG, Johnson WL Jr, Huber KC, Rutherford BD: Successful percutaneous coronary intervention of a chronic total occlusion is associated with increased long-term survival; a 20 year experience in 2007 patients: CIRC Vol 102, No 18, October 2000; II-390:1900.

24. Marso SP, Huber KC, Coen MM, Giorgi LV, Laster SB, Rutherford BD: Insulin treated diabetes mellitus is associated with a marked increase in in-hospital mortality following urgent PCI: a continuation of the oral vs insulin treatment debate: CIRC Vol 102, No 18, October 2000; II-391.

25. Marso SP, Giorgi LV, Johnson WL, Laster SB, Huber KC, O’Keefe JH, Rutherford BD.  Diabetes Mellitus is Associated with an Increased Risk of In-Hospital Death Following Elective Percutaneous Coronary Intervention: An Analysis of 18,309 Patients. (Oral Presentation 48th Annual Scientific Session, ACC 2000): J AM Coll Cardiol 2000; 35(2):72 A.

26. Giocondo MJ, Marso SP, Huber KC, Giorgi LV, Laster SB, Rutherford BD: Acute long-term Outcomes for a New Generation Stent: Experience in 441 Patients with the Medtronic AVE GFX Stent: (Poster Presentation 48th Annual Scientific Session, ACC 2000). JAM Coll Cardiol 2000; 35(2):78A

27. Patel, VB, Marso, SP, Jones, PG, Laster, SB, Huber, KC, Giorgi, LV, Johnson, WL, Rutherford, BD: Multivessel Stenting: Is It Time to Reconsider Recommendations for Coronary Artery Bypass Surgery?  JACC, March 2001;37(2):51A.

28. Gustafson G, Marso SP, Huber KC, Johnson WL, Laster SB, McCallister BD, Giorgi LV, Rutherford BD.  Percutaneous Coronary Intervention (PCI) in Octogenarians:  Is It Appropriate?  Circ 2001;104(17):II-703.

29. Corpus RA, Marso SP, House JA, Huber KC, Laster SB, Johnson WL, Giorgi LV, Daniel WC, Rutherford BD.  Multivessel vs Infarct Artery-Only Percutaneous Coronary Intervention in Patients with Multivessel Disease and Acute Myocardial Infarction.  Am J Cardiol TCT 2003 Sept 15-17;92(6A):118L.

30. Safley DM, Rutherford BD, House JA, Khanna A, Johnson WL, Giorgi LV, Huber KC, Laster SB, Barth CW, Grantham JA, Marso SP.  Factors Impacting Five-Year Survival After Percutaneous Coronary Intervention for Chronic Total Occlusion.  J Am Coll Cardiol 2004;43(5):57A.

31. Safley DM, House J, Barberena JE, Huber KC, Rutherford B, Marso S, K.U., Saint Luke’s Hospital, Mid America Heart Institute: Diabetic Vulnerable Plaque: an in Vivo Analysis of Coronary Atherosclerotic Plaque Phenotype: Study involving 113 patients with IVUS and VH: May 2006, Vol, 67, issue 5 - 817, D-18

32. Barberena JE, Safley DM, Huber KC, House JA, Rutherford BD, Marso SP.  Continuous Glucose Monitoring Demonstrates Poor Glycemic Control in the Peri Percutaneous Intervention Time Period for Diabetes Mellitus Patients.  Cath & Cardiovasc Interv 2006 May 12;67(5):792, C-14.

33. Barberena JE, House J, Safley DM, Huber KC, Rutherford BD, Marso SP, Saint Luke’s Hospital, Mid America Heart Institute: Plasma Adiponectin is Inversely Associated with Atherosclerotic Plaque Burden: May 2006, Vol, 67, issue 5 – 817, D19

34. Barberena JE, House J, Huber KC, Rutherford BD, Marso SP, Saint Luke’s Hospital, Mid America Heart Institute: Unique Patient Phenotypes Associate with Unique Plaque Phenotype Patterns: May 2006, Vol, 67, issue 5 – 817, D20

35. McCrary J, Barberena J, House J, Safley DM, Daniels L, Huber KC, Rutherford BD, Marso SP.  Clinical Factors Associated with Vulnerable Plaque: An Intravascular Ultrasound Radiofrequency Data Analysis.  Circ 2006 Oct;114(18):II-506.

36. Main, ML, Huber KC, Magalski A, “Contract Enhanced Transesophageal Echocardiographic Guidance of Left Atrial Appendage Closure Device Implantation.” Journal of the American Society of Echocardiography; April 2010.

 

BOOK CHAPTER:

Pathology of Post Interventional Coronary Restenosis.  Huber KC, Garratt KN, Schwartz RS, Edwards WD.  In Schwartz RS, ed.  Coronary Restenosis, Cambridge, UK; Blackwell Scientific Publications, Inc. 1993:192-204.  

 

On Staff At

  • Anderson County Hospital
  • Hedrick Medical Center
  • Saint Luke's Cushing Hospital
  • Saint Luke's East Hospital
  • Saint Luke's Hospital of Kansas City
  • Saint Luke's North Hospital–Barry Road
  • Saint Luke's North Hospital–Smithville
  • Saint Luke's South Hospital
  • Wright Memorial Hospital